^
    BIOMARKER:

    RET M918T

    i
    Other names: RET, Ret Proto-Oncogene, Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret, Cadherin-Related Family Member 16, Rearranged During Transfection, RET Receptor Tyrosine Kinase, Cadherin Family Member 12, Proto-Oncogene C-Ret, CDHF12, CDHR16, PTC, Ret Proto-Oncogene (Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease), Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease 1, RET-ELE1, HSCR1, MEN2A, MEN2B, RET51, MTC1
    Entrez ID:
    5979
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    RET M918T
    Thyroid Gland Medullary Carcinoma
    cabozantinib capsule
    Sensitive: A2 - Guideline
    RET M918T
    Thyroid Gland Medullary Carcinoma
    pralsetinib
    Sensitive: C3 – Early Trials
    RET M918T
    Thyroid Gland Medullary Carcinoma
    sorafenib
    Sensitive: C3 – Early Trials
    RET M918T
    Thyroid Gland Medullary Carcinoma
    selpercatinib
    Sensitive: C3 – Early Trials
    RET M918T
    Thyroid Gland Medullary Carcinoma
    everolimus + vandetanib
    Sensitive: C4 – Case Studies
    RET M918T
    Thyroid Gland Medullary Carcinoma
    everolimus
    Sensitive: C4 – Case Studies
    RET M918T
    Thyroid Gland Medullary Carcinoma
    vandetanib
    Sensitive: C4 – Case Studies
    RET M918T
    Thyroid Gland Medullary Carcinoma
    sunitinib
    Sensitive: C4 – Case Studies
    RET M918T
    Thyroid Gland Carcinoma
    XMD15-44
    Sensitive: D – Preclinical
    RET M918T
    Thyroid Gland Medullary Carcinoma
    AMG 706
    Resistant: D – Preclinical
    RET M918T
    Thyroid Gland Carcinoma
    HG-6-63-01
    Sensitive: D – Preclinical
    RET M918T
    Thyroid Gland Papillary Carcinoma
    AZD1480
    Sensitive: D – Preclinical
    RET M918T
    Thyroid Gland Carcinoma
    ALW-II-41-27
    Sensitive: D – Preclinical